Why Alcobra (ADHD) Stock Hit a One-Year Low Today

NEW YORK (TheStreet) — Shares ofaAlcobraa plummeted to a 52-week low of $6.16 on Monday after the company announced its experimental formulation of vitamin B6 called MDX failed in a phase III trial. MDX failed to improve symptoms of attention-deficit hyperactivity disorder (ADHD) in adults when compared to a placebo, according to the trial's results. Alcobra emphasized the results changed when …

from Content Keyword RSS http://ift.tt/1xX58rd http://ift.tt/eA8V8J

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s